(PRINCETON, NJ – Oct. 15, 2021)

WCG IRB announced today that five of its thought leaders will be presenting at MAGI’s Clinical Research vConference – Fall 2021. This year’s conference will be held online from October 18-28.

“At WCG IRB, we have a proven record of providing the highest quality ethical reviews for today’s complex clinical research challenges, which is backed by the decades of expertise our subject matter experts hold across all therapeutic categories. We consider sharing our knowledge with peers to be an integral part of our role as the industry leader, and there is simply no substitute for decades of clinical experience. While at the MAGI vConference, these leading perspectives will bring even greater scientific, medical, ethical, and regulatory expertise required to support our clients, as we assist them in making the right decisions related to planning and conducting studies,” said Dawn Flitcraft, President of WCG IRB.

Below is an overview of the WCG IRB speaking presentations:

Monday, October 25

R. Bert Wilkins, JD, MHA, CIP, Regulatory Chair Director at WCG IRB, will partner with Jeanna Julo, BA, BA CCRP, Quality Improvement and Compliance Officer at UCSF Medical Center, to discuss regulatory nuances and best practices during their presentation entitled “Good Clinical Practice and Human Subject Protection Regulatory Fine Points (C293)” at 2:30 p.m.

In parallel, Jeffrey Cooper, MD, MMM, Parkinson’s Disease Patient Advocate at WCG IRB will participate in the panel discussion entitled “What We Can Learn from Experienced Study Participants (L867),” led by Steve Smith, President, Patient Advocacy at WCG Clinical. They will be joined by Dorelia Rivera, an Inflammatory Disorder Clinical Trial Mom and Patient Advocate, and Marissa Penrod, a Duchenne Muscular Dystrophy Clinical Trial Mom and Patient Advocate who will discuss their personal experiences as caregivers.

Then at 4 p.m., David Borasky, MPH, CIP, Vice President, IRB Compliance at WCG IRB will ask “Would You Approve This? Study Approvals at the Edge (C590).” He will discuss some of the gray areas that IRBs must navigate with Bruce Gordon, MD, Assistant Vice Chancellor at the University of Nebraska Medical Center.

Wednesday, October 27

WCG IRB cell and gene therapy experts will present foundational sessions on this rapidly evolving field. Christopher Doyle, PhD, Director, Institutional Biosafety Committee (IBC) Services will discuss “Gene-Based Medicines: New Treatments for Old Problems (T878)” at 11:00 a.m. He will partner with Patient Advocate Luke Pembroke to describe how cell and gene therapies work, when they are applicable, and what the patient experience is like.

They will be followed by Daniel Kavanagh, PhD, RAC, Senior Scientific Advisor, Gene Therapy at WCG IRB, who will address “The Regulatory Landscape in Cell and Gene Therapies (T879)” at 12:30 pm. Together with Dominique Pichard, MD, Chief Science Officer at the International Rett Syndrome Foundation, Dr. Kavanagh will provide an overview of the applicable U.S. Food and Drug Administration and National Institutes of Health ethical and biosafety regulations and guidance.

MAGI attendees can schedule meetings with members of the WCG IRB team at https://www.wcgirb.com/contact-us/. Experts from WCG’s Clinical Trial Solutions Division will also be presenting at the conference.

Interested parties can learn more about this event at https://www.wcgclinical.com/events/magi-fall-2021.


WCG IRB provides the highest quality ethical reviews of clinical research protocols and studies. WCG IRB was created by combining five IRBs with different areas of expertise and geographical reach – Western IRB (WIRB), the world’s first independent ethical review board, Copernicus Group IRB, New England IRB, Aspire IRB, and Midlands IRB. WCG IRB has more than 50 years’ experience and more than 200 members on AAHRPP-accredited boards. Since 2000, WCG IRB has also provided IBC administration and review services to nearly 800 institutions and evaluated more than 400 human gene transfer protocols. For more information, please visit www.wcgirb.com or follow us on Twitter @WCGClinical or LinkedIn.